Navigation Links
Quest PharmaTech Announces a Review of Strategic Alternatives to Enhance Shareholder Value
Date:2/2/2009

TSX Venture: QPT

EDMONTON, Feb. 2 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer and dermatological conditions, announces that it has entered into an agreement with Loewen, Ondaatje, McCutcheon Limited ("LOM") to provide financial advisory services in connection with various business development opportunities.

"The current capital market conditions have provided us with alternative strategic opportunities including mergers and acquisitions, strategic partnerships and monetizing certain capital assets," said Dr. Madiyalakan, Chief Executive Officer for Quest. "In order to position the Company for future growth and to increase shareholder value, we are evaluating these alternatives with the help of LOM." In addition, Quest would also like to leverage the valuable clinical and preclinical data it has generated from its proprietary SonoLight Technology, as well as the continuing support from its current shareholders.

Quest also announces the grant of 300,000 stock options to its three independent board members at an exercise price of $0.15. All allocations will be subject to approval of the TSX Venture Exchange.

Quest has four product candidates in development based on its proprietary SonoLight Technology. SL017, for hair removal, is currently in a Phase II, 110-patient clinical trial. SL017, for the treatment of actinic keratosis, has been shown to be safe and well tolerated in a Phase 1 dose-escalation clinical trial. SL017, for the treatment of acne, has completed evaluation in a Phase 1 clinical trial. SL052, which is being developed to treat prostate cancer, has completed preclinical studies.

About Quest PharmaTech Inc. Quest is a publicly traded, Alberta-based pharmaceutical company committed to the development and commercialization of new pharmaceutical products. It i
'/>"/>

SOURCE Quest PharmaTech Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... SEABROOK, N.H. , May 22, 2013 /PRNewswire/ ... of the Year 2013" by Business NH Magazine.  ... recognized Granite State organizations that distinguish themselves with ... are very proud to receive this honor," said ... Superior Controls.  "As with any recognition, this award ...
(Date:5/22/2013)... Toronto, Ontario (PRWEB) May 22, 2013 ... of advanced sound therapy for tinnitus treatment. AudioNotch ... Destination Hearing . With clinic locations in both ... trusted provider of audiology and hearing services. AudioNotch's ... Zabell locations. , Upon entering a Destination Hearing ...
(Date:5/22/2013)... Envera announced today that Michael McErlean ... McErlean has an extensive background in cell production and ... career. , Mike Matheny, President and Owner ... Mike join our team”. “Mike’s background is perfectly suited ... and downstream processing equipment”, added Matheny. “Mike’s hands ...
(Date:5/21/2013)... , May 22, 2013 ... drug-only formulation of glycopyrronium bromide designed using Prosonix, particle ... company developing a portfolio of inhaled Respiratory Medicines ... study with PSX1002 that will assess its effect on ... doses in patients with moderate to severe chronic obstructive ...
Breaking Biology Technology:Superior Controls of Seabrook, NH named Business of the Year for 2013 by Business NH Magazine 2AudioNotch Tinnitus Treatment Launches Partnership With Destination Hearing 2Envera Appoints Michael McErlean Fermentation Manager 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4
... Mass.,  Feb. 4, 2011 The ALS ... elected Anil Godhwani, a successful Silicon Valley entrepreneur, to ... "nonprofit biotechnology" organization with a mission to discover and ... sclerosis (ALS, Lou Gehrig,s Disease). (Logo: ...
... Pharmacyclics, Inc. (Nasdaq: PCYC ) today ... second quarter that ended December 31, 2010.Recent Developments & ... Btk Inhibitor PCI-32765 in B-cell malignanciesPharmacyclics has designed a ... lymphocytic leukemia and diffuse large B-cell lymphoma to inform ...
... Boston College has been awarded a $1 million grant ... of university researchers developing a new microscope that uses ... and macroscopic matter with significantly improved clarity. The ... new class of microscopes known as "superlenses," which function ...
Cached Biology Technology:ALS Therapy Development Institute Appoints Anil Godhwani to Board of Directors 2Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 2Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 3Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 4Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 5Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 6Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 7Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 8Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 9Boston College receives W.M. Keck Foundation funding for nanoscale optical microscope 2
(Date:5/22/2013)... of pollinating insects and wild plants have slowed in ... led by the University of Leeds and the Naturalis ... dramatic reductions in the diversity of species in Britain, ... , But the picture brightened markedly after 1990, with ... bees, hoverflies and wild plants. , Professor ...
(Date:5/21/2013)... long time that some creatures evolve more quickly than ... But it may be that height plays a role, ... U. S. National Evolutionary Synthesis Center. , In ... journal Nature Communications , Lanfear and colleagues report ... a database of global patterns in plant height for ...
(Date:5/21/2013)... considered in the management of natural resources, and ... help them recognize and respond to the relationships ... , Place-Based Conservation: Perspectives from the Social ... Northwest Research Station,s Linda Kruger, can help managers ... is published by Springer Verlag and is available ...
Breaking Biology News(10 mins):Encouraging signs for bee biodiversity 2Encouraging signs for bee biodiversity 3Small but speedy: Short plants live in the evolutionary fast lane 2
... in the Earth and its atmosphere, such as melting polar ... of global climate change. But changes in climate can wreak ... habitat for plant and animal species. In a series of ... Meeting, climate change scientists will discuss how temperature-induced habitat loss ...
... into an epidemic, reflected in soaring rates of type ... elevated cholesterol. What hasn,t been as clear is ... a pediatric research program on Friday suggested obesity prevention ... children reach a "tipping point" in a progression that ...
... a genetically induced lack of filaggrin, a key protein ... the origin of allergies. In a large study on ... Mnchen and the Technische Universitt Mnchen found that about ... filaggrin gene, which raise the risk to develop atopic ...
Cached Biology News:Climate change and species distributions 2Climate change and species distributions 32 years old -- a childhood obesity tipping point? 2When our protective armor shows weakness 2
MOUSE ANTI PORCINE SLA 1:FITC Immunogen: Porcine peripheral blood mononuclear cells....
An excellent carbonyl-reactive FRET quencher paired with Trp or Tyr. Minimum Purity: 95%. Abs(max): ~350 nm; Em(max): none. Solvent System:DMSO or DMF....
EDG-6 (1)...
Complexin-1/2 (FL-134)...
Biology Products: